Clinical significance of Annexin A2 expression in Bladder urothelial carcinoma.




Guo, Christina
Chaudhary, Panka J.


Journal Title

Journal ISSN

Volume Title



Purpose: Bladder urothelial carcinoma (BLCA) is a highly malignant cancer, representing the 8th most common cause of cancer death in the US. The unpredictable disease course of BLCA necessitates an accurate biomarker to guide screening, prognosis, and treatment. Our objective was to investigate AnxA2 expression in tumor tissues of bladder urothelial carcinoma patients to determine AnxA2 association with bladder urothelial cancer and implicate AnxA2 as a potential prognostic marker. Methods: We utilized data from The Cancer Genome Atlas (TCGA) to observe AnxA2 gene expression in BLCA and its association with overall survival. Additionally, we quantified AnxA2 protein expression in tumor tissues of BLCA patients via immunohistochemistry. Results: In our analysis of TCGA data, AnxA2 mRNA expression was significantly higher in BLCA tumor tissues compared to normal bladder tissues. In addition, AnxA2 expression was significantly associated with higher tumor stage and grade as well as non-papillary tumor subtypes. The high expression of AnxA2 in BLCA patients was significantly correlated to decreased survival [hazard ratio (HR), 1.78; 95% confidence interval (CI), 1.3-2.44] as compared to low expression. In addition, we found that AnxA2 was significantly upregulated in tumor tissues of bladder urothelial carcinoma patients compared with adjacent non-cancerous bladder tissues. Conclusion: AnxA2 is overexpressed in BLCA patients, which is related to the advanced clinicopathological variables and adverse prognosis of patients with BLCA.